The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
 
Jesús Fuentes Antrás
No Relationships to Disclose
 
Samah El Ghamrasni
No Relationships to Disclose
 
Jinfeng Zou
No Relationships to Disclose
 
Aaron Dou
No Relationships to Disclose
 
Mitchell J. Elliott
No Relationships to Disclose
 
Lisa Avery
No Relationships to Disclose
 
Scott Victor Bratman
Employment - Adela
Leadership - Adela
Stock and Other Ownership Interests - Adela
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.; Co-inventor of patent application pending related to detection of HPV circulating cell-free DNA. (Inst); Co-inventor of patents related to cell-free DNA methylation analysis technology. (Inst)
 
David W. Cescon
Consulting or Advisory Role - AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; INFLEX; Lilly; Merck; Novartis; Pfizer; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
Expert Testimony - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Inivata
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)